Exai Bio
RNA & AI Liquid Biopsy for Early Cancer Detection
- Headquarters
- Palo Alto, California
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- exai.bio
- Total Funding
- $67.5M
- Last Round
- $67.5M Series ADec 2023
- Rounds
- 2
About
Exai Bio is an RNA-based liquid biopsy company using noncoding RNA and AI for early cancer detection from blood draws.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Dec 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...